Search for: "Par Pharmaceutical Companies, Inc" Results 61 - 80 of 90
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
26 Sep 2010, 8:41 pm by Patent Docs
Par Pharmaceutical Companies, Inc. et al. 1:10-cv-07310; filed September 22, 2010 in the Southern District of New York • Plaintiff: Biovail Laboratories International SRL • Defendants: Par Pharmaceutical Companies, Inc.; Par Pharmaceuticals, Inc. [read post]
12 May 2010, 5:49 pm by Randall Reese
The members of the Creditors' Committee are: Par Pharmaceutical, Inc. [read post]
25 Feb 2010, 11:18 am by Beck, et al.
That’s par for the course with this kind of thing. [read post]
2 Dec 2009, 11:05 am by dbmadmin
On December 2, 2009, the FTC announced an order settling charges that Watson Pharmaceuticals, Inc. [read post]
18 Oct 2009, 5:42 pm
  Judge Brown found that the patent in question, US Patent No. 5,565,473, was valid and enforceable, and [...]...FTC Sues Regarding AndroGel Patent Settlement The Federal Trade Commission has filed a complaint in federal district court challenging agreements in which Solvay Pharmaceuticals, Inc. paid generic drug makers Watson Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. to delay generic competition… [read post]
12 Oct 2009, 12:38 pm
Citigroup Global Market, Inc. has filed a motion to dismiss an action against it by KV Pharmaceuticals Co. arising out of sales of auction rate securities, according to an August 25 article in Law360 by Christine Caufield entitled "Citigroup Argues KV Pharma Knew ARS Risks. [read post]
8 Jul 2009, 7:04 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com]   Highlights this week included: Kenya: Manufacturers, public heath interests clash over anti-counterfeit law; AIDS patients to bring Constitutional challenge (Intellectual Property Watch) (Afro-IP) (Intellectual Property Watch) Humira (Adalimumab) – US: Largest patent verdict in history – Abbott to pay $1.67 billion to Centocor because Humira found to… [read post]
3 Jun 2009, 5:49 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com]   Highlights this week included: Singulair (Montelukast) – US: Merck & Co’s Singulair patent challenged on $50K bounty (Patent Baristas) (GenericsWeb)   General Docs at BIO (Panel addresses narrowing scope of biotech patents – Patent Docs), (‘Perfect storm’ super session – Patent Docs) (Biotech… [read post]
3 Jun 2009, 5:49 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com]   Highlights this week included: Singulair (Montelukast) – US: Merck & Co’s Singulair patent challenged on $50K bounty (Patent Baristas) (GenericsWeb)   General Docs at BIO (Panel addresses narrowing scope of biotech patents – Patent Docs), (‘Perfect storm’ super session – Patent Docs) (Biotech… [read post]
26 May 2009, 6:27 am
Amylin's public Indenture [2] contains a common change in control provision giving noteholders the right to put their notes to the company at par if "at any time Continuing Directors do not constitute a majority of the Company's Board of Directors". [read post]
8 May 2009, 8:00 am
You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: [duncanbucknell.com]   Highlights this week included: Mircera (Methoxy polyethylene glycol-epoetin beta) – US: Federal Circuit revises Amgen v ITC (Patently-O) (Patent Baristas) (ITC 337 Law Blog) (Hal Wegner) (Patent Docs)   General Alicia Greenidge to step down as Director of IFPMA (Intellectual Property Watch) Flu crisis could lead to compulsory licences (Managing… [read post]
22 Apr 2009, 6:14 am
Citigroup has been hit with a $30 million auction-rate securities lawsuit filed by Braintree Laboratories, Inc., a specialty pharmaceutical company, reported Christine Caufield in an April 17, 2009 article posted on Law360.com. [read post]
27 Mar 2009, 8:00 am
(Intellectual Property Watch) Two final thoughts on big pharma acquisitions (IP finance) Brazil: Patent term cutbacks in Brazil and pharmaceutical pipelines – IP Think Tank podcast 23 March 2009 (IP Think Tank) Brazil: Patent term cutbacks - Lobbying, intellectual property and superior courts (IP Think Tank) Brazil: Patent term extension (PTE) under TRIPs revisited and reviewed by Superior Court of Justice (IP tango) Denmark: Harmonisation in Denmark: Patents covering… [read post]
20 Mar 2009, 2:05 am
Sterling Drug, Inc., 416 F.2d 417, 426 (2d Cir. 1969).District of Columbia: McNeil Pharmaceutical v. [read post]
6 Mar 2009, 7:03 am
The complaint also names generic pharmaceutical companies Watson Pharmaceuticals, Par Pharmaceuticals and Paddock Laboratories. [read post]
23 Dec 2008, 7:00 pm
It was withdrawn at Par Pharmaceuticals based on the Board of Directors' commitment to adopt the policy in 2009. [read post]